In this article:
Blurbs

Analysts Offer Insights on Healthcare Companies: AlloVir (ALVR), Jazz Pharmaceuticals (JAZZ) and Seagen (SGEN)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AlloVir (ALVRResearch Report), Jazz Pharmaceuticals (JAZZResearch Report) and Seagen (SGENResearch Report) with bullish sentiments.

AlloVir (ALVR)

Leerink Partners analyst Mani Foroohar maintained a Buy rating on AlloVir yesterday. The company’s shares closed last Tuesday at $11.20.

According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of -19.7% and a 31.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and 4D Molecular Therapeutics.

Currently, the analyst consensus on AlloVir is a Strong Buy with an average price target of $42.00.

See Insiders’ Hot Stocks on TipRanks >>

Jazz Pharmaceuticals (JAZZ)

Leerink Partners analyst Marc Goodman reiterated a Buy rating on Jazz Pharmaceuticals yesterday. The company’s shares closed last Tuesday at $150.02.

According to TipRanks.com, Goodman is a 1-star analyst with an average return of -0.5% and a 43.2% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $202.25 average price target, a 36.6% upside from current levels. In a report released today, BMO Capital also reiterated a Buy rating on the stock with a $202.00 price target.

Seagen (SGEN)

In a report released yesterday, Andrew Berens from Leerink Partners maintained a Buy rating on Seagen. The company’s shares closed last Tuesday at $145.70.

According to TipRanks.com, Berens has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.7% and a 44.0% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.

Seagen has an analyst consensus of Moderate Buy, with a price target consensus of $191.73, representing a 31.1% upside. In a report issued on January 3, William Blair also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALVR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More